Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Europe sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q3 2020
9
Period ended Sep 30, 2020
Change on a year earlier
-25.0%
12 in Q3 2019
History
16 quarters
Since Q4 2016
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2020 | Sep 30, 2020 | 9 | -25.0% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 6 | -60.0% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 11 | -31.2% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 11 | -47.6% | Form 10-K (filed 2020-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 12 | -42.9% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 15 | -25.0% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 16 | 0.0% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 21 | +23.5% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 21 | +320.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 20 | – | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 16 | – | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 17 | -22.7% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 5 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 0 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 0 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 22 | – | Form 8-K (gildq42017exh991.htm, filed 2018-02-06) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Europe sales ($M) ($M), quarterly Q4 2016–Q3 2020 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_vosevi_eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.